KALV
Kalvista Pharmaceuticals Inc
Price:  
9.09 
USD
Volume:  
219,045.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

KALV WACC - Weighted Average Cost of Capital

The WACC of Kalvista Pharmaceuticals Inc (KALV) is 7.3%.

The Cost of Equity of Kalvista Pharmaceuticals Inc (KALV) is 10.90%.
The Cost of Debt of Kalvista Pharmaceuticals Inc (KALV) is 5.00%.

Range Selected
Cost of equity 9.40% - 12.40% 10.90%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 5.00% - 5.00% 5.00%
WACC 6.6% - 8.0% 7.3%
WACC

KALV WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 1.21 1.34
Additional risk adjustments 0.0% 0.5%
Cost of equity 9.40% 12.40%
Tax rate 26.20% 27.00%
Debt/Equity ratio 1 1
Cost of debt 5.00% 5.00%
After-tax WACC 6.6% 8.0%
Selected WACC 7.3%